Open company graph database — free web & API
Login

Eisai America, Inc.

Eisai Inc. (U.S.A.)Aliasエイズアイ・アメリカ株式会社Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
10,917
Related companies
10
§01

Basic information

BASIC
Head office
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Chief executive
Haruo Naito
Capital
44,986 JPY
Employees (non-consolidated)
2,998 people
Employees (consolidated)
10,917 people
Start date
1941-12-06
End date
§02

Websites

1 DOMAINS
§03

Business

8
Research and development of pharmaceuticalsManufacture of pharmaceuticalsSale of pharmaceuticalsImport and export of pharmaceuticalsPharmaceutical development and marketingResearch and development of drugsManufacturing of pharmaceutical productsCorporate venture capital
§04

Related companies

10 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Eisai Korea Inc.
Group Customer
Eisai Australia Pty. Ltd.
Group
Eisai New Zealand Ltd.
Group
Eisai Pharmaceuticals Africa (Pty) Ltd
Group
Eisai Co., Ltd.
Group
Eisai (Malaysia) Sdn. Bhd.
Group
SampleNet Corporation
Group
EA Pharma Co., Ltd.
Group
Eisai Pharmaceuticals India Pvt. Ltd.
Group
HI-Eisai Pharmaceutical, Inc.
Customer
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

43 EVENTS

Nihon Eisai Co., Ltd.'s contraceptive suppository : Sampoon : , researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government.Sources

Nihon Eisai Co., Ltd. launches cardiotonic : Neophyllin : in Japan.Sources

Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product : Chocola BB Tablets : in Japan.Sources

Nihon Eisai Co., Ltd. launches motion sickness remedy : Travelmin : in Japan.Sources

The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today.Sources

Eisai rolls out its first three-year mid-term plan.Sources

Eisai's Head Office building is completed in Tokyo.Sources

Eisai opens its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan.Sources

Eisai is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges.Sources

Gastrointestinal remedies : Saclon : and : Saclon Tablets : , recognizable for their distinct green hue even today, are launched in Japan.Sources

Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan.Sources

The Kawashima Plant is completed in Gifu, central Japan.Sources

Kawashima Plant opening ceremony.Sources

Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president.Sources

A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.Sources

Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.Sources

PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia.Sources

Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.Sources

Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.Sources

Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively.Sources

Metabolic cardiotonic : Neuquinon : is launched in Japan.Sources

Naturally derived vitamin E product : Juvelux : is launched in Japan.Sources

Eisai's founder Toyoji Naito passes away at age 89.Sources

Peripheral neuropathy treatment : Methycobal : is launched in Japan.Sources

Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.Sources

Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.Sources

Eisai Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States.Sources

Anti-Alzheimer's agent : Aricept : is launched in the United States, the United Kingdom and Germany.Sources

Pariet : is launched under the brand name : AcipHex : in the United States.Sources

Eisai Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.Sources

Eisai acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States.Sources

Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.Sources

Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.Sources

Halaven is launched in the United States.Sources

H3 Biomedicine Inc. is established as a research subsidiary in the United States.Sources

Fycompa is launched in the United States.Sources

Lenvima is launched in the United States, Japan and Europe.Sources

Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.Sources

Eisai agrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A.Sources

Eisai Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation.Sources

DAYVIGO (insomnia treatment) is launched in the United States and Japan.Sources

Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States.Sources

LEQEMBI is granted traditional approval by the FDA.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑